A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment
Latest Information Update: 02 Jun 2021
At a glance
- Drugs ANC 501 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 06 Dec 2018 Status changed from active, no longer recruiting to discontinued as per sponsor decision.
- 07 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2017 Status changed from not yet recruiting to recruiting.